tradingkey.logo

Mineralys Therapeutics Announces Positive Topline Results From Phase 2 Trial Of Lorundrostat For The Treatment Of Hypertension

ReutersJun 17, 2025 11:38 AM

- Mineralys Therapeutics Inc MLYS.O:

  • MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 EXPLORE-CKD TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION IN SUBJECTS WITH CKD AND ALBUMINURIA

  • MINERALYS THERAPEUTICS INC - LORUNDROSTAT DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE

  • MINERALYS THERAPEUTICS INC - SERIOUS ADVERSE EVENTS REPORTED IN 3% OF SUBJECTS DURING LORUNDROSTAT TREATMENT

  • MINERALYS THERAPEUTICS INC - LORUNDROSTAT 25 MG ACHIEVES 9.3 MMHG REDUCTION IN SYSTOLIC BLOOD PRESSURE

  • MINERALYS THERAPEUTICS INC - LORUNDROSTAT SHOWS 31% REDUCTION IN URINE ALBUMIN-TO-CREATININE RATIO

  • MINERALYS THERAPEUTICS INC - ONE SUBJECT DISCONTINUED LORUNDROSTAT DUE TO ELEVATED POTASSIUM

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI